Ciphergen to Present Data at IGCS
Ciphergen Biosystems, Inc. has announced multiple presentations with its collaborators supporting the use of protein biomarkers to help discriminate women with ovarian cancer from those with benign tumors and to help predict survival in patients with ovarian cancer.
The presentations will be made at the International Gynecologic Cancer Society (IGCS) Biennial Meeting in Santa Monica, Calif., October 14-18.
"A diagnostic test is needed that has adequate predictive value to stratify patients with a pelvic mass into high risk of ovarian cancer from those with low risk," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer for Ciphergen Biosystems.
"As published in the Journal of the National Cancer Institutes in February, studies have shown that women with ovarian cancer have better outcomes when triaged to a gynecologic oncologist for treatment."
"The presentations at IGCS are further evidence supporting the development of Ciphergen's panel of biomarkers to help differentiate women with ovarian cancer and thereby aid in insuring that they receive the most appropriate medical attention."
Each abstract has been presented on Sunday, October 15, 2006 from 12:30-1:30 p.m. during Poster Session 1: Ovarian in the Exhibition Area.
Abstract: A Panel of Seven Biomarkers Improves Specificity in Discriminating Malignant from Benign Pelvic Masses
Collaborators: The Danish Cancer Society, John Hopkins Medical Institutions, University of Copenhagen
Abstract: Novel Biomarkers that Predict Survival in Patients with Ovarian Cancer
Collaborator: University of Copenhagen
Abstract: Evaluation of Pre-Analytic Influence of Sample Collection/Handling Methodologies on Serum Proteome is Key in Biomarker Discovery and Assay Development
Collaborators: University College London, Royal Holloway College